The Elekta Unity magnetic resonance radiation therapy (MR/RT) system has gotten its FDA 510(k) premarket notification and is now ready for sale and clinical use in the U.S.
“Since receiving CE mark in June 2018, Elekta Unity has been transforming the care of cancer patients in Europe, and we are excited that this cutting-edge technology is now commercially available to U.S. patients,” Elekta president and CEO Richard Hausmann said in a statement
, adding that the Unity will make possible the development of personalized, precision radiation therapy regimens optimized for safety and efficacy.
The Unity will “make radiation therapy a viable treatment option for more patients,” he added, thanking all involved in the MR-linac consortium and MR technology partner, Royal Philips.
The Unity is designed to simultaneously deliver radiation dose and visualization of tumors and adjacent healthy tissue in the form of high-quality MR images, employing integrated tools for possible treatment adjustments to match current anatomical information in a treatment session.
“Unity is a tremendous leap forward in our ability to tailor radiation therapy to each patient’s tumor and anatomy, and to adapt treatment in real time as the tumor changes shape and position relative to organs at risk,” said Dr. Christopher Schultz, chair of the Elekta MR-linac Consortium.
He called the new technology “fundamentally” transformational in terms of the development and implementation of therapy regimens that will permit clinicians “to achieve optimal outcomes for our patients.”
Back in September, Elekta forecast
a net sales compound annual growth rate of 8-10 percent through its 2022/2023 financial year.
“We have improved our margin and cash flow and have returned to high growth. We are now in a good position to realize our vision,” said Hausmann in a statement, noting that “the future of our industry is in precision radiation medicine, including diagnostic quality imaging at the point of treatment, real-time adaptive treatment planning, data-driven personalization and intelligent automation.”
Its predictions follow the company's recent decision to sell its magnetoencephalography (MEG) business
to Croton Healthcare subsidiary York Instruments as part of an initiative to restructure and strategically prioritize its treatment solutions and oncology informatics portfolio, agreements set up between the radiotherapy manufacturer and other parties over the past year.
They also are based on recent partnerships established between the radiotherapy manufacturer and other parties, such as Proton Partners International, which agreed in April to buy and install
Elekta's MR-linac system at a network of cancer centers under development in the U.K. The deal calls for the acquisition of five systems for an order value of £25 million ($34,915,950), to be installed over a three-year period.
In March, the company paired with IBM to bridge care gaps in cancer care globally
, through a partnership combining Elekta’s MOSAIQ Oncology Information System and IBM’s Watson for Oncology platform. The move aims to level the radiotherapy and oncology treatment field to put care in developing nations on par with high-end markets, such as the U.S. and Western Europe.
“If we look at all cancers in terms of effective treatment and five-year survival, in a high market like the U.S. or Western Europe, we’re expecting about a fifty percent survival rate,” Andrew Wilson, vice president of Elekta’s global marketing digital portfolio, said at the time. "Standardization of oncology care means closing the oncology treatment gap for all ... But if you look at different countries with lower GDP, these are when co-statistics start to drop, and in some articulate disease areas it’s very evident of the inequality that exists across different markets.”